Skip to Content

Baxter International Inc BAX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Baxter's 2021 Outlook Slightly Weaker Than Expected Due to COVID Challenges; Shares Fairly Valued

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Baxter beat EPS expectations slightly in the fourth quarter, but its 2021 earnings outlook is a little weaker than we expected. While we may adjust our estimates for 2021 slightly, we do not anticipate materially changing our $73 fair value estimate at first glance. The shares appear about fairly valued.

Read Full Analysis

Company Profile

Business Description

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2020 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (6%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (23% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (18% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

Contact
One Baxter Parkway
Deerfield, IL, 60015
T +1 224 948-2000
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Classic Growth
Employees 50,000

Related